CompletedNot Applicable

Optic Nerve Sheath Diameter / Eyeball Transverse Diameter Ratio and Prognosis of Sepsis Associated Encephalopathy

Egypt89 participantsStarted 2023-03-01

Plain-language summary

Sepsis is associated with a mortality rate of 20-25%, with significant increase in case of associated comorbidities or shock. SAE is one of the most common forms of encephalopathy encountered in critically ill patients, with increased ICP as a possible underlying mechanism. Many studies revealed that ONSD is a valuable ICP monitoring tool. Also, ONSD/ETD ratio, according to previous studies, seemed to be more reliable than ONSD alone in predicting neurological outcomes of comatosed patients. The present study will assess the correlation between US-ONSD/ETD ratio and the prognosis of SAE in critically ill patients.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Acceptance of one of patient's 1st degree relatives.
✓. Age ≥ 18 and ≤ 65 years old of both sexes.
✓. Sedated or unconscious patients and on invasive mechanical ventilation.
✓. Patients diagnosed with sepsis associated encephalopathy (SAE);

Exclusion criteria

✕. Ocular and/or optic nerve pathology; e.g., ocular trauma or surgery, previous ocular pathology as glaucoma or cataract, conjunctival or orbital edema, vitreous hemorrhage and optic nerve disease or injury.
✕. Intracranial pathology; e.g., central nervous system (CNS) infection, cerebrovascular accident, cerebral hemorrhage, brain trauma or tumor, and any previous neurosurgical procedure.
✕. Toxic or metabolic encephalopathy, e.g., alcohol toxicity, liver or kidney disease.
✕. Serious co-morbidities that could affect life expectancy, e.g., hematopathy or cancer.

What they're measuring

Correlation between US ratio of ONSD/ETD and neurologic outcome 3 months following ICU discharge in critically ill patients with SAE.

Timeframe: 3 months following ICU discharge

Trial details

NCT IDNCT05918705

SponsorZagazig University

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2024-08-01

View on ClinicalTrials.gov More Sepsis-associated Encephalopathy trials